W

WuXi XDC Cayman Inc
HKEX:2268

Watchlist Manager
WuXi XDC Cayman Inc
HKEX:2268
Watchlist
Price: 26.7 HKD 6.37% Market Closed
Market Cap: 32B HKD
Have any thoughts about
WuXi XDC Cayman Inc?
Write Note

WuXi XDC Cayman Inc
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

WuXi XDC Cayman Inc
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
W
WuXi XDC Cayman Inc
HKEX:2268
Total Receivables
ÂĄ985.8m
CAGR 3-Years
177%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Total Receivables
ÂĄ10.1B
CAGR 3-Years
23%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Total Receivables
ÂĄ2.9B
CAGR 3-Years
26%
CAGR 5-Years
25%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Total Receivables
ÂĄ6.8B
CAGR 3-Years
13%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Total Receivables
ÂĄ4.3B
CAGR 3-Years
31%
CAGR 5-Years
31%
CAGR 10-Years
33%
Genscript Biotech Corp
HKEX:1548
Total Receivables
$299.5m
CAGR 3-Years
47%
CAGR 5-Years
43%
CAGR 10-Years
N/A
No Stocks Found

WuXi XDC Cayman Inc
Glance View

Market Cap
32B HKD
Industry
Life Sciences Tools & Services

WuXi XDC Cayman Inc is a CN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Wuxi, Jiangsu and currently employs 1,113 full-time employees. The company went IPO on 2023-11-17. WuXi XDC Cayman Inc is a holding company primarily engaged in the provision of contract research, development and manufacturing services (CRDMO) for antibody drug conjugates (ADCs) and a wider range of bioconjugate drugs. The firm conducts its businesses through two segments. Research Services on Fee-for-service(FFS) Basis segment providing research services to its customers through FFS contracts. The Research Services on Full-time-equivalent(FTE) Basis segment providing a project team of employees dedicated to the customer's studies for a specific period of time. Based on biopharmaceuticals and small molecule drugs, the Company also provides comprehensive cross-domain services, covering the discovery, process development and good manufacturing practice (GMP) production of bioconjugated drugs, linkers and payloads. The firm conducts its business in domestic and foreign markets.

Intrinsic Value
28.5 HKD
Undervaluation 6%
Intrinsic Value
Price
W

See Also

What is WuXi XDC Cayman Inc's Total Receivables?
Total Receivables
985.8m CNY

Based on the financial report for Dec 31, 2023, WuXi XDC Cayman Inc's Total Receivables amounts to 985.8m CNY.

What is WuXi XDC Cayman Inc's Total Receivables growth rate?
Total Receivables CAGR 3Y
177%

Over the last year, the Total Receivables growth was 89%. The average annual Total Receivables growth rates for WuXi XDC Cayman Inc have been 177% over the past three years .

Back to Top